to-BBB Technologies BV, of Leiden, the Netherlands, said that the Dutch Ministry of Economic Affairs, Agriculture and Innovation has granted the company an Innovation credit of about $1.7 million to support a Phase I/II study of the company's lead compound, 2B3-101, in women with brain metastases of breast cancer.